ArticleTransplantation direct2025

Feasibility and Safety of Ex Vivo Delivery of Rituximab to Lung Allografts in Transplant Recipients at High Risk for Epstein-Barr Virus-associated Posttransplant Lymphoproliferative Disorder.

Victor H Ferreira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.